![glp 1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight NEJM Interview: Amanda Banks on](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3585945231426876830)
glp 1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight NEJM Interview: Amanda Banks on
USD21.48
USD42.48
Pay in 4 interest-free payments of $5.37 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
![glp 1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight NEJM Interview: Amanda Banks on](https://i.ytimg.com/vi/Dsxqh02uAiU/hq720.jpg?sqp=-oaymwE7CK4FEIIDSFryq4qpAy0IARUAAAAAGAAlAADIQj0AgKJD8AEB-AG2CIACuAiKAgwIABABGCkgUyh_MA8=&rs=AOn4CLCHL4qN0vUCJ4h5bHryZxAaQKG7HA)
![glp 1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight NEJM Interview: Amanda Banks on](https://www.nejm.org/cms/asset/ce1e2adf-f3d9-473d-88ac-ae012685c50e/nejmoa2028198_f1.jpg)
![glp 1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight NEJM Interview: Amanda Banks on](https://images.squarespace-cdn.com/content/v1/535bcb2fe4b05fe61b320c51/ff763443-50b9-464e-8c57-8a57698eb810/image7.png)
![glp 1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight NEJM Interview: Amanda Banks on](https://evidence.nejm.org/cms/10.1056/EVIDoa2500173/asset/d46fac1d-6511-43aa-8e5a-a16bb0443306/assets/images/large/evidoa2500173_t1.jpg)
